Routine_2560x664
EXEMPLARILY DEPICTED USE CASES IN CLINICAL ROUTINE
Exemplarily Depicted Use Case in Clinical Routine
Prostate_screening_arrow

mint Lesion TM for Oncological Screening 

 

mint Lesion™ supports radiologists in performing the radiological read for oncological screening. The most frequently used reading profile is PI-RADS v2.1, which includes new, dedicated reading procedures for the assessment of prostate images obtained using multi-parametric MRI, including T2 weighted images, DCE, and DWI (ADC, b-value).

 

By means of standardized graphical prostata schemes and integrated help with representative images for different scorings, you can easily document and communicate lesion location, as well as the generated lesion scoring according to PI-RADS classification.

mint Lesion TM for Oncological Staging

 

mint Lesion™ supports radiologists in performing the radiological read for oncological staging. The TNM classification for malignancies is the most common approach to document the stage of a cancer disease. The staging heavily relies upon significant key observations in medical image data – therefore, radiological reports are crucial for the assessment of potential therapy opportunities.

 

mint Lesion™ knows about the intricacies of particular criteria and guidelines and automatically determines the stage of disease based on radiological image annotations, classifications, and further clinical parameters. The profiles include a variety of TNM tumor entities, staging and transplant scoring of liver disease.

Lung_Staging_arrow
Therapy_Response_arrow

mint Lesion TM for Therapy Response Evaluation

 

mint Lesion™ supports radiologists in performing the follow-up assessment. Therapy monitoring based on standardized criteria are increasingly applied in clinical routine. Meanwhile, more and more oncologists demand results, which were evaluated and assessed in compliance with predefined criteria – e. g. RECIST.

 

With mint Lesion™, you can conduct such sophisticated evaluations easily and within a short time. Assessments conform with international established standards or follow your adapted guidelines. Furthermore, you do not need to master any statistical analysis, mint Lesion™ performs the interpretation for you automatically.

Request a Test Drive for mint Lesion TM Submit NowX

APPLICABLE READING PROFILES IN mint Lesion TM
ACR RADS® and Oncological Staging (TNM 8 and specifics)
Therapy Response Evaluation
  • Lung
  • Colon / Rectum
  • Pancreas
  • Stomach / Esophagus
  • Head / Neck
  • Prostate | PI-RADS
  • Liver | LI-RADS
  • RECIST 1.1
  • irRECIST
  • imRECIST
  • irRC
  • Cheson
  • CHOI
  • PCWG3
  • IWCLL
  • PERCIST
  • RECIST 1.0
  • iRECIST
  • mRECIST HCC
  • mRECIST Mesothelioma
  • RANO / RANO-BM
  • Lugano
  • WHO
  • LYRIC
  • RECIST 1.1 / iRECIST
icon for additional information
  • Customizable Profiles
HOW mint Lesion TM IMPROVES YOUR REPORTING

In most cases, very individual
unstructured reports are written in prose.

Medical prose report

mint Lesion™ generates holistic and comprehensive reports
with automated determination of clinical results.

RECIST graphics
RECIST report mixed response
Efficient Workflows and Reporting compliant with RECIST and Other Quantitative Imaging Standards in Cancer Research and Clinical Practice

Modern targeted therapies play an increasingly important role in the treatment of cancer patients in the era of personalized medicine. Clinical studies already demonstrated considerable tumor response under treatment with new agents such as Sorafenib in HCC and RCC, or Imatinib in GIST. In the face of these modern targeted therapies and increasingly multi-modal therapy approaches, new challenges and opportunities arise for oncological procedures and radiological image-based diagnoses.

 

A major pitfall in tumor response monitoring is the increasing incidence of mixed response in targeted therapies. A typical example is the treatment with Vemurafenib in metastatic melanoma with specific B-RAF mutation. Response to Vemurafenib is typically not durable because of suddenly developing resistances. An early detection of disease progression provides improved outcome of subsequent therapies, e.g. with the monoclonal antibody Ipilimumab.

 

A 44-year-old patient with metastatic melanoma treated with Vemurafenib was radiologically assessed according to the RECIST 1.1 guidelines. A first follow-up CT scan eight weeks after treatment start (Baseline) showed mixed response… Read more

icon for explanation of seamless integration
Seamless integration with your IT-infrastructure

Start mint Lesion™ directly from your RIS / PACS while preserving the working context. Relevant image data is automatically synchronized with your PACS and results can be integrated into your RIS report.

 

Click here for more technical information